Healthcare Services

Lung Cancer Liquid Biopsy Market Revenue Expected to Reach $2.42 Billion by 2030 with 16.7% CAGR

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Lung Cancer Liquid Biopsy Market In 2026 And What Value Is Projected For 2030?

The lung cancer liquid biopsy market size has experienced rapid growth in recent years. This market is expected to expand from $1.12 billion in 2025 to $1.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.0%. The expansion observed in the past can be linked to factors such as rising lung cancer incidence rates, the limitations inherent in tissue biopsy procedures, breakthroughs in molecular diagnostics, the widespread availability of circulating biomarker technologies, and an increase in oncology research endeavors.

The lung cancer liquid biopsy market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 16.7%. This expansion during the forecast period is attributable to the increasing demand for precision oncology solutions, the broadening of liquid biopsy clinical applications, a rise in the adoption of companion diagnostics, the growing integration of AI-driven data analysis, and an increased focus on early cancer screening programs. Significant trends expected during this period include the rising adoption of non-invasive diagnostic techniques, increased utilization of NGS-based liquid biopsy tests, a growing demand for early cancer detection, the expansion of personalized oncology diagnostics, and enhanced integration of bioinformatics platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

What Drivers Are Influencing The Lung Cancer Liquid Biopsy Market?

The rising occurrence of lung cancer is projected to drive expansion within the lung cancer liquid biopsy market in the coming period. This condition involves the unchecked proliferation of atypical cells in the lungs, frequently stemming from tobacco use and exposure to environmental factors. The primary reason for the rise in lung cancer cases is ongoing tobacco consumption, as smoking introduces carcinogens to the lungs, stimulating irregular cell development. A lung cancer liquid biopsy aids in identifying genetic mutations linked to cancer and tumor DNA through a blood specimen, facilitating prompt diagnosis, choice of treatment, and tracking of disease advancement or therapeutic effectiveness. For example, a report from the American Cancer Society (ACS), a U.S.-based nonprofit organization, indicated in January 2023 that approximately 238,340 individuals, comprising 117,550 men and 120,790 women, are projected to receive a lung cancer diagnosis in 2023, with an anticipated 127,070 people succumbing to the illness. Consequently, the growing prevalence of lung cancer is fueling the expansion of the lung cancer liquid biopsy market.

What Are The Key Segments Of The Lung Cancer Liquid Biopsy Market?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Which Trends Are Shaping The Future Of The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are prioritizing the development of technological advancements, including blood-based lung cancer screening tests, to enhance early detection capabilities, improve diagnostic accuracy, and enable non-invasive, real-time monitoring of tumor progression and treatment response. A blood-based lung cancer screening test represents a non-invasive method that analyzes specific biomarkers in the bloodstream to identify the presence of lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology company, launched FirstLook Lung, a blood-based liquid biopsy test specifically designed to aid in early lung cancer detection. This test leverages fragmentomics to detect early lung cancer with high sensitivity and features a 99.8% negative predictive value, making it a convenient and accessible initial step for at-risk individuals. Its purpose is to improve early detection, increase screening rates, and help direct further imaging resources to those most likely to benefit.

Who Are The Leading Companies Operating In The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Read the full lung cancer liquid biopsy market report here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Lung Cancer Liquid Biopsy Market?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lung Cancer Liquid Biopsy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

Lung Cancer Diagnostic And Screening Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Liquid Biopsy Global Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Lung Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795